Efficacy of tegaserod in chronic constipation in men

American Journal of Gastroenterology

Volumn 102, Issue 2, 2007, Pages 362-370

  Fried, Michael ^a   Johanson, John F ^b   Gwee, Kok Ann ^c   Wagner, Amy ^d   Pecher, Eckhard ^d   Rueegg, Peter ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Rockford Gastroenterology Associates   (United States)

^c GLENEAGLES HOSPITAL   (Singapore)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; LAXATIVE; LOPERAMIDE; PLACEBO; SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL PAIN; ANALYTICAL PARAMETERS; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; CHRONIC DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFECATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FLATULENCE; GASTROINTESTINAL MOTILITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; NAUSEA; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; SCREENING; STATISTICAL SIGNIFICANCE; SUBACUTE THYROIDITIS; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CONSTIPATION; DEFECATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 33846549058     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00988.x     Document Type: Article

References (31)

1. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum 1989;32:1-8.
2. Talley NJ, Jones M, Nuyts G, et al. Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003;98:1107-11.
3. Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S3-10.
4. Higgins PD, Johanson JF. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 2004;99:750-9.
5. Walter S, Hallbook O, Gotthard R, et al. A population-based study on bowel habits in a Swedish community: Prevalence of faecal incontinence and constipation. Scand J Gastroenterol 2002;37:911-6.
6. Garrigues V, Galvez C, Ortiz V, et al. Prevalence of constipation: Agreement among several criteria and evaluation of the diagnostic accuracy of qualifying symptoms and self-reported definition in a population-based survey in Spain. Am J Epidemiol 2004;159:520-6.
7. Cheng C, Chan AO, Hui WM, et al. Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation: a population-based study. Aliment Pharmacol Ther 2003;18:319-26.
8. Drossman DA, Corazziari E, Talley NJ. Rome II: The functional gastrointestinal disorders. McLean, VA: Degnon Associates, 2000.
9. Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002;47:2222-30.
10. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005;100:S1-21.
11. Kim DY, Camilleri M. Serotonin: A mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-709.
12. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003;3(suppl 2):S25-34.
13. Cash BD, Chey WD. Review article: The role of serotonergic agents in the treatment of patients with primary constipation. Aliment Pharmacol Ther 2005;22:1047-60.
14. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-51.
15. Degen L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821-6.
16. Prather C, Camilleri M, Zinsmeister A, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
17. 4 receptor agonist induces cAMP-mediated CI efflux from rat chondrocytes. Gastroenterology 1999;116:G287.
18. Schikowski A, Thewissen, Mathis MC, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002;14:221-7.
19. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577-85.
20. Sabate J, Bouhassira D, Poupardin C, et al. Antinociceptive effect of tegaserod in female IBS constipated patients. Gastroenterology 2005;128(suppl 2):A-468.
21. Johanson J, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2:796-805.
22. Kamm M, Müller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100:362-72.
23. O'Donnell L, Virjee J, Heaton K. Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate. BMJ 1990;300:439-40.
24. Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology 2001;120:557-60.
25. Kamm MA. Review article: The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:343-51.
26. Chey WD, Chang L, Harris L, et al. Incidence of ischemic colitis in clinical trial and post-marketing surveillance amongst patients using alosetron after blinded adjudication. Gastroenterology 2005;128(suppl 2):T1139.
27. Bradette M, Moennikes H, Carter F, et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): Efficacy and safety in a 6 month global study. Gastroenterology 2004;126:A42.
28. Brinker AD, Mackay AC, Prizont R. Tegaserod and ischemic colitis. N Engl J Med 2004;351:1361-4.
29. Singh G, Mithal A, Kahler K, et al. Patients with irritable bowel syndrome have a high risk of developing colon ischemia. Gut 2004;53:A66.
30. Cole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004;99:486-91.
31. Schiller LR. New and emerging treatment options for chronic constipation. Rev Gastroenterol Disord 2004;4(suppl 2):S43-51.